Zimmer Biomet (NYSE:ZBH) (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.
The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices. In addition to implantable devices, Zimmer Biomet provides surgical power tools, instruments, biologics and bone graft materials, as well as preoperative planning, surgeon training and other clinical support services. The company has invested in digital tools and surgical technologies designed to support perioperative planning and improve procedural efficiency.
Zimmer Biomet traces its roots to long-established legacy businesses in the orthopaedics sector; Zimmer was founded in the early 20th century and Biomet began operations in the late 20th century, and the two companies combined in 2015 to form the current organization. Today the company serves markets around the world, commercializing products and supporting clinical customers across the Americas, Europe, Asia-Pacific and other regions through a network of sales, distribution and service operations.
Operating as a publicly traded company, Zimmer Biomet emphasizes research and development, regulatory compliance and strategic partnerships to advance its product pipeline and clinical offerings. Its business strategy centers on innovation in musculoskeletal care, expanding access to surgical solutions, and supporting clinicians with training and post-market services that aim to improve patient outcomes.
